New drugs and gene therapies designed to treat cancer, rare diseases, etc. are justifiably commanding high prices. However, if they don’t work, payments shouldn’t be required.
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.